Yu Qingyuan, Zhou Xian, Kapini Rotina, Arsecularatne Anthony, Song Wenting, Li Chunguang, Liu Yang, Ren Junguo, Münch Gerald, Liu Jianxun, Chang Dennis
Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of Basic Medical Sciences of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China.
Xiyuan Clinical Medical College, Beijing University of Chinese Medicine, Beijing 100029, China.
Medicines (Basel). 2024 Jul 18;11(7):14. doi: 10.3390/medicines11070014.
Cytokine storm (CS) is the main driver of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS) in severe coronavirus disease-19 (COVID-19). The pathological mechanisms of CS are quite complex and involve multiple critical molecular targets that turn self-limited and mild COVID-19 into a severe and life-threatening concern. At present, vaccines are strongly recommended as safe and effective treatments for preventing serious illness or death from COVID-19. However, effective treatment options are still lacking for people who are at the most risk or hospitalized with severe disease. Chinese herbal medicines have been shown to improve the clinical outcomes of mild to severe COVID-19 as an adjunct therapy, particular preventing the development of mild to severe ARDS. This review illustrates in detail the pathogenesis of CS-involved ARDS and its associated key molecular targets, cytokines and signalling pathways. The therapeutic targets were identified particularly in relation to the turning points of the development of COVID-19, from mild symptoms to severe ARDS. Preclinical and clinical studies were reviewed for the effects of Chinese herbal medicines together with conventional therapies in reducing ARDS symptoms and addressing critical therapeutic targets associated with CS. Multiple herbal formulations, herbal extracts and single bioactive phytochemicals with or without conventional therapies demonstrated strong anti-CS effects through multiple mechanisms. However, evidence from larger, well-designed clinical trials is lacking and their detailed mechanisms of action are yet to be well elucidated. More research is warranted to further evaluate the therapeutic value of Chinese herbal medicine for CS in COVID-19-induced ARDS.
细胞因子风暴(CS)是严重冠状病毒病2019(COVID-19)中,严重急性呼吸综合征冠状病毒2(SARS-CoV-2)诱导的急性呼吸窘迫综合征(ARDS)的主要驱动因素。CS的病理机制相当复杂,涉及多个关键分子靶点,这些靶点会将自限性和轻度的COVID-19转变为严重的、危及生命的疾病。目前,强烈推荐使用疫苗作为预防COVID-19导致的严重疾病或死亡的安全有效治疗方法。然而,对于风险最高或因重症住院的患者,仍然缺乏有效的治疗选择。中药已被证明作为辅助疗法可改善轻至重度COVID-19的临床结局,特别是预防轻至重度ARDS的发展。本综述详细阐述了CS相关ARDS的发病机制及其相关的关键分子靶点、细胞因子和信号通路。特别针对COVID-19从轻症发展到严重ARDS的转折点确定了治疗靶点。综述了临床前和临床研究中,中药与传统疗法在减轻ARDS症状以及针对与CS相关的关键治疗靶点方面的作用。多种中药配方、提取物和单一生物活性植物化学物质,无论是否与传统疗法联用,均通过多种机制表现出强大的抗CS作用。然而,缺乏来自大型、设计良好的临床试验的证据,其详细作用机制尚待充分阐明。有必要开展更多研究,以进一步评估中药对COVID-19诱导的ARDS中CS的治疗价值。